MicroStockProfit.com: CUR reports net loss of $5,096,983 for third-quarter of 2009

MicroStockProfit.com announces an investment report featuring Neuralstem Inc. (AMEX:CUR). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/ads/CUR

Neuralstem Inc. (CUR) is a biotechnology company focused on developing and commercializing human neural stem cell technology in the field of regenerative medicine. The Company manufactures its cells both in-house and on an outsource basis. It uses these cells in its research grant and collaborative programs. The Company outsources all the manufacturing and storage of its stem cells to be used in pre-clinical works to Charles River Laboratories Inc., of Wilmington, Massachusetts. The Charles River facility has the capacity to be used for cell processing under the U.S. Food and Drug Administration determined good manufacturing practices in quantities sufficient for its current pre-trial and anticipated future clinical trial needs.

Message Board Search for CUR: http://www.boardcentral.com/boards/CUR

In the report, the analyst notes:

"For the third quarter of 2009, the Company reported a net loss of $5,096,983, or $0.15 per share, compared with a net loss of $3,177,957 or $0.10 per share, for the comparable 2008 period. The increase was due to a non-cash charge related to a change in accounting for certain warrants, offset in part by reductions in other expense categories.

"The heart of CUR's therapeutic cell development programs centers on its ability to isolate and grow human neural stem cells from diverse regions of the developing human brain and spinal cord.
 
"The Company has a very proactive plan for obtaining and protecting its stem cell Intellectual Property, not just in the United States, but worldwide.  In addition to its stem cell intellectual property, the Company has been active in licensing important intellectual property rights for newly developed devices and equipment that will be required to optimize delivery of its stem cell therapeutics through surgical transplantation into the brain and spinal cord."